- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00682279
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
April 15, 2015 updated by: GlaxoSmithKline
A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination With Lapatinib in Subjects With Advanced Solid Tumors
This is an open-label, Phase I study of oral topotecan administered in combination with lapatinib in subjects with advanced solid tumors.
This Phase I study will evaluate the safety, tolerability, and pharmacokinetics of oral topotecan administered in combination with lapatinib.
This study will be conducted in two parts.
Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the maximum-tolerated dose (MTD) regimen of the combination (dose escalation phase).
In Part 2 of the study, the dose of oral topotecan will be escalated while lapatinib will be given initially as fixed doses.
The primary objective of the study is to determine the MTD regimen of oral topotecan administered for five-consecutive days every 21 days in combination with daily lapatinib in subjects with advanced solid tumors.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must provide signed, written informed consent.
- Subjects must be ≥18 years of age.
- Subjects must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
- Subjects must have histologically or cytologically confirmed diagnosis of cancer.
- Subjects must have advanced solid malignancies without an established standard of care therapy option OR progression following the most recent therapy.
- Subjects may have measurable lesion(s) according to RECIST criteria.
- Subjects with stable CNS metastases or leptomeningeal involvement are eligible only if they are not taking oral steroids or CYP450 enzyme-inducing anticonvulsants.
- Subjects must have a LVEF ≥ 50% or ≥ lower limit of normal for the institution based on MUGA scan or ECHO. The same method of cardiac evaluation must be used consistently throughout the study.
- Subjects in the expanded cohort phase must have archived tumor tissue samples available for biomarker analysis. It is preferable that a paraffin-embedded tissue block from archived tumor tissue from the primary tumor be submitted.
- Subjects must provide informed consent and blood samples to the pharmacogenetics research.
- Subjects must be able to swallow and retain oral medications.
- Subjects must have adequate hematological, hepatic, and renal function as defined: Hematologic: absolute neutrophil count (ANC) ≥1.5 X 10^9/L, hemoglobin ≥10 g/dL, platelets ≥100 X 10^9/L; Hepatic: serum bilirubin≤ upper limit of normal (ULN), AST and ALT ≤ 5 x ULN if documented liver metastases, AST and ALT ≤ 3 X ULN without liver metastases; Renal: calculated creatinine clearance ≥50 mL/min.
- A female is eligible to enter and participate in this study if she is of:
- Non-childbearing potential (i.e., women with functioning ovaries who have a current documented hysterectomy, or bilateral tubal ligation, or women who are post-menopausal defined as documented absence of menses for > 12 months or women with a documented bilateral oophorectomy);
- Childbearing potential (i.e. women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility.) This category includes women with oligomenorrhoea (severe), women who are perimenopausal, and young women who have begun to menstruate. These subjects must have a negative serum pregnancy test at Screening (≤7 days prior to administration of first dose of investigational product), and agree to use adequate contraception beginning at least 2 weeks prior to the first does of investigational product and for 28 days after the final dose of investigational product. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
- An intrauterine device with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the clinical trial, and for at least 28 days after the last dose of investigational product.
- Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).
- Oral contraceptives are not reliable due to potential drug-drug interaction.
- Male subjects with a female partner of childbearing potential are eligible to enter and participate in the study if they practice adequate barrier methods of contraception (see above) or abstinence during the study from the first dose of investigational product until 3 months after the final dose of investigational product.
Exclusion Criteria:
- Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of investigational product or who have unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.
- Subjects who have received an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product.
- Subjects taking prohibited medications listed in the protocol.
- Subjects with a known immediate or delayed hypersensitivity or untoward reaction to topotecan or other related compounds, or to drugs chemically related to lapatinib. These include other anilinoquinazolines, such as gefitinib, erlotinib, or other chemically-related compounds.
- Subjects with presence of uncontrolled infection.
- Subjects with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
- Subjects with uncontrolled or symptomatic angina, arrhythmias.
- Subjects with Class II to IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- Women who are pregnant or lactating.
- Subjects who have received an allogeneic bone marrow transplant.
- Subjects with any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study.
- Subjects with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- Subjects with clinical history, current alcohol or illicit drug use which, in the judgment of the investigator, would interfere with the subject's ability to comply with the dosing schedule and protocol-specified evaluations.
- Subjects with current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: This is a single-arm, dose escalation
This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose.
This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib.
This study will be conducted in two parts.
Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
|
This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose.
This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib.
This study will be conducted in two parts.
Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The maximum-tolerated dose (MTD) regimen of the combination will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle.
Time Frame: Study cancelled prior to FCI.
|
Study cancelled prior to FCI.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events and changes from baseline in laboratory values, ECGs, Multiple gated Acquisition (MUGA) scanning/Echocardiogram (ECHO), and vital signs will be evaluated to assess safety and tolerability.
Time Frame: Study cancelled prior to FCI.
|
Study cancelled prior to FCI.
|
Topotecan pharmacokinetic parameters may include AUC(0-∞), AUC(0-τ), Cmax, tmax, t½, and tlag,
Time Frame: Study cancelled prior to FCI.
|
Study cancelled prior to FCI.
|
alone and in combination with lapatinib. Lapatinib pharmacokinetic parameters may include AUC(0-τ), Cτ, Cmax, tmax, and tlag, alone and in combination with topotecan.
Time Frame: Study cancelled prior to FCI.
|
Study cancelled prior to FCI.
|
Disease assessments will be obtained every two cycles and will be recorded as tumor response (e.g. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD]).
Time Frame: Study cancelled prior to FCI.
|
Study cancelled prior to FCI.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Anticipated)
March 1, 2011
Study Completion (Anticipated)
March 1, 2011
Study Registration Dates
First Submitted
May 20, 2008
First Submitted That Met QC Criteria
May 20, 2008
First Posted (Estimate)
May 22, 2008
Study Record Updates
Last Update Posted (Estimate)
April 17, 2015
Last Update Submitted That Met QC Criteria
April 15, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LPT109098
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on oral topotecan (SK&F-104864); lapatinib (GW572016)
-
GlaxoSmithKlineCompletedAdenocarcinomaNetherlands, United States, Peru
-
GlaxoSmithKlineCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLeukemiaUnited States, Australia, Canada
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsCompletedNeoplasms, BreastRussian Federation, China, Brazil, Hong Kong, Pakistan, Peru, Thailand, Ukraine
-
National Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CarcinomaUnited States, Singapore
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedTivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsAdult Solid NeoplasmUnited States